Jason Lucas


Jason Lucas advises clients on a range of projects involving evidence generation, analysis, and strategy.

Jason has a background in pharmacy and medical claims data management providing guidance to payers and life sciences companies that are utilizing, processing, and applying the results of data in optimal ways.

Before joining Avalere, Jason held various leadership positions in the pharmaceutical and healthcare consulting industries, including BMS and Novartis, where he led strategic forecasting and analytics for cardiovascular health and molecular diagnostics. Jason also held senior roles at ZS Associates, Paraxel, and IQVIA, leading client engagements to drive real world evidence strategy and execution across US and the European and Asia Pacific regions.

Jason holds a bachelor’s degree in psychology and political science form SUNY Buffalo and a master’s in political science with a concentration in social research methodologies from SUNY Stony Brook.

Authored Content

When utilizing and acquiring data, life sciences companies should consider these top questions and key implications for their 2024–2025 strategic plans.

A major cyberattack has disrupted medical and pharmacy claims processing and is expected to impact how medical claims are submitted and paid in the future.

ChatGPT marked an AI inflection point decades in the making—with implications for health economics and outcomes research.

In this installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #6: Artificial Intelligence.

The rapid expansion of artificial intelligence (AI) across healthcare holds the promise of dramatically altering not only diagnosis and treatment but also research, risk assessment, drug development, care management, and even insurance and payment systems.